The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Supra-additive effect of IMO-4200, a novel TLR7 and TLR8 dual agonist, with rituximab and cytotoxics in preclinical models of hematologic malignancies.
D. Wang
Employment or Leadership Position - Idera Pharmaceuticals
M. Precopio
Employment or Leadership Position - Idera Pharmaceuticals
M. Reardon
Employment or Leadership Position - Idera Pharmaceuticals
T. Lan
Employment or Leadership Position - Idera Pharmaceuticals
J. X. Tang
Employment or Leadership Position - Idera Pharmaceuticals
E. R. Kandimalla
Employment or Leadership Position - Idera Pharmaceuticals
A. S. Bexon
Consultant or Advisory Role - Idera Pharmaceuticals
N. La Monica
Employment or Leadership Position - Idera Pharmaceuticals
S. Agrawal
Employment or Leadership Position - Idera Pharmaceuticals